Protonix News and Research

RSS

Access to NAbs testing important for MS therapy management

Teva Neuroscience today announced results at the 62nd American Academy of Neurology Annual Meeting which demonstrated that eliminating barriers to neutralizing antibodies (NAbs) testing significantly impacted multiple sclerosis (MS) treatment choices in patients receiving interferon beta (IFNβ) therapies.

17 Apr 2010

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from several studies demonstrating that laquinimod, a novel, investigational once-daily oral immunomodulator for relapsing remitting multiple sclerosis (RRMS) may have neuroprotective properties in addition to its anti-inflammatory effects.

16 Apr 2010

Copaxone achieves one million patient years of experience in treatment of RRMS

Teva Pharmaceutical Industries, Ltd. announced today that Copaxone® (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA).

13 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

FDA grants final approval for Teva Pharmaceutical Industries' generic Hyzaar and Cozaar

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).

8 Apr 2010

U.S. Court finds Teva Pharmaceutical Industries' Seasonique patent valid and enforceable

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Duramed, now Teva Women's Health, brought suit in the District of Nevada against Watson alleging infringement of Teva's patent as a result of Watson's filing of an Abbreviated New Drug Application (ANDA) for Seasonique®.

2 Apr 2010

Teva Pharmaceutical Industries' Gemzar patent litigation: U.S. court issues decision

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the Southern District of Indiana issued a decision yesterday on two patents for Gemzar® (gemcitabine); the compound patent expiring on November 15, 2010, and a method of use patent expiring on May 7, 2013.

2 Apr 2010

Teva Pharmaceutical Industries settles generic eloxatin patent infringement litigation

Teva Pharmaceutical Industries Ltd. announced today that patent infringement litigation pertaining to Teva's generic version of sanofi-aventis and Debiopharm's Eloxatin (oxaliplatin injection) has been dismissed by the United States District Court for the District of New Jersey pursuant to a settlement between the parties.

1 Apr 2010

FDA grants tentative approval for Teva Pharmaceutical Industries' generic Argatroban ANDA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of the anticoagulant, Argatroban® injection, 100mg/mL.

26 Mar 2010

Teva Pharmaceutical Industries receives right to market generic version of Schering’s Temodar

Teva Pharmaceutical Industries Ltd. announced today that the parties to the patent litigation regarding Barr’s U.S. generic version of Schering’s Temodar® have entered into an agreement pending resolution of Schering’s appeal to the Federal Circuit of the U.S. District Court’s decision holding the ‘291 Patent unenforceable.

19 Mar 2010

Teva Pharmaceutical Industries to acquire ratiopharm for €3.625 billion

Teva Pharmaceutical Industries Ltd. announced today that it has entered into a definitive agreement to acquire ratiopharm, Germany’s second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of €3.625 billion. The transaction is subject to certain conditions including relevant regulatory approvals. On a pro forma basis, the combined company would have had 2009 revenues of $16.2 billion. Teva expects to complete the transaction by year-end 2010.

18 Mar 2010

Concurrent use of proton-pump inhibitor and clopidogrel does not elevate cardiovascular risk

Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel - a drug that prevents blood clots - were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the National Heart, Lung, and Blood Institute at the National Institutes of Health.

16 Mar 2010

Generic Hyzaar and Cozaar litigation: Court of Appeals rules in favor of Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Court of Appeals for the District of Columbia Circuit has ruled in Teva’s favor by overturning a July 31, 2009, district court decision which held that Teva forfeited 180-day marketing exclusivity for its generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).

2 Mar 2010

Study: EIB may affect lives and health of public if not addressed properly

For the vast majority of the general public, respiratory symptoms such as shortness of breath, wheezing or coughing are a common part of the exercise experience. However, together with chest tightness, noisy breathing and trouble taking a deep breath, these six symptoms make up the phenomenon known as exercise-induced bronchospasm (EIB), which has physical, emotional and psychological consequences if not addressed properly.

2 Mar 2010

Teva Pharmaceutical announces clinical study results of Copaxone in RRMS patients

Teva Pharmaceutical Industries Ltd. today announced the publication of data from the 15-year clinical study with Copaxone® (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis (RRMS) patients. The data were published in the February issue of the journal Multiple Sclerosis.

26 Feb 2010

Teva Pharmaceutical Industries announces fourth-quarter and full-year 2009 financial results

Teva Pharmaceutical Industries Ltd. today reported record results for the quarter and year ended December 31, 2009.

16 Feb 2010

Teva Pharmaceuticals USA settles famciclovir patent litigation with Novartis

Teva Pharmaceutical Industries Ltd. today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva’s U.S. generic version of Novartis’ Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims for patent infringement and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.

16 Feb 2010

Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that they have amended the marketing and distribution agreement for oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS). Under the new agreement, Teva extended its marketing and distribution rights to include the Nordic and Baltic regions, previously held by Active Biotech. Active Biotech will receive a higher royalty rate for sales in these territories compared to the royalty rate set under the original licensing agreement signed in 2004 for sales in the rest of the world.

9 Feb 2010

Teva Pharmaceutical Industries reaches settlement in principle to resolve claims under federal, state False Claims Acts

Teva Pharmaceutical Industries Ltd. announced today that several of its subsidiaries in the United States reached a settlement in principle to resolve claims brought by Ven-A-Care of the Florida Keys, Inc. on behalf of the United States, Texas, Florida, and California under federal and state False Claims Acts.

6 Feb 2010

New resources to support Teva Pharmaceutical Industries' Tjet injector system now available

Teva Pharmaceutical Industries Ltd. announced today the availability of new resources to support the recently introduced Tjet® injector system, a needle-free device designed to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] brand human growth hormone (hGH) to children who have growth failure due to inadequate secretion of normal endogenous growth hormone.

3 Feb 2010